This study is for patients with a type of blood cancer called Chronic Myeloid Leukemia in Chronic Phase (CML-CP). The study aims to test a new medicine called olverembatinib. In Part A, it will compare this new drug with a standard treatment called bosutinib. Part B will focus on patients with a specific change in their cancer cells, known as the T315I mutation. Some patients from Part A might switch to the new drug if they don't respond well to bosutinib.
- Duration: The study involves a series of visits and treatments, but the exact length isn't specified.
- Eligibility: Patients must be 18 years or older and have previously tried other treatments.
- Risks: Patients with certain infections or allergies should not participate.
To join, you must be an adult with CML-CP and have tried other treatments. Pregnant or nursing women cannot participate. If you have specific mutations or allergies, this study might not be for you. Discuss with your doctor to see if this study is a good fit for you.
How understandable was the trial content above?
Hard to understand
Easy to understand